Maravai LifeSciences Holdings Inc
MRVI2.265USD
+0.045+2.03%
Horário de mercado （ET）Cotações atrasadas em 15 min
326.06MValor de mercado
PerdaP/L TTM
Mais detalhes de Maravai LifeSciences Holdings Inc Empresa
Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
Informações da empresa
Código da empresaMRVI
Nome da EmpresaMaravai LifeSciences Holdings Inc
Data de listagemNov 20, 2020
CEOMr. Bernd Brust
Número de funcionários570
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 20
Endereço10770 Wateridge Circle Suite 200
CidadeSAN DIEGO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal92121
Telefone18585460004
Sitehttps://www.maravai.com/
Código da empresaMRVI
Data de listagemNov 20, 2020
CEOMr. Bernd Brust
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Bernd Brust
Mr. Bernd Brust
Chief Executive Officer, Director
Chief Executive Officer, Director
2.00M
--
Mr. Rajesh J. (Raj) Asarpota
Mr. Rajesh J. (Raj) Asarpota
Chief Financial Officer
Chief Financial Officer
500.00K
--
Mr. Kurt Oreshack
Mr. Kurt Oreshack
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
439.87K
+196.03%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Chairman of the Board
Independent Chairman of the Board
365.89K
+172.22%
Ms. Christine Dolan
Ms. Christine Dolan
Executive Vice President, General Manager - Cygnus Technologies
Executive Vice President, General Manager - Cygnus Technologies
335.06K
+0.72%
Ms. Rebecca Buzzeo
Ms. Rebecca Buzzeo
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
224.73K
-28.71%
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Director
Independent Director
199.91K
+80.47%
Ms. Susannah Gray
Ms. Susannah Gray
Independent Director
Independent Director
169.91K
+110.36%
Dr. Murali K. Prahalad, Ph.D.
Dr. Murali K. Prahalad, Ph.D.
Independent Director
Independent Director
154.61K
+136.16%
Mr. Luke Joseph Marker
Mr. Luke Joseph Marker
Director
Director
138.06K
+182.23%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Bernd Brust
Mr. Bernd Brust
Chief Executive Officer, Director
Chief Executive Officer, Director
2.00M
--
Mr. Rajesh J. (Raj) Asarpota
Mr. Rajesh J. (Raj) Asarpota
Chief Financial Officer
Chief Financial Officer
500.00K
--
Mr. Kurt Oreshack
Mr. Kurt Oreshack
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
439.87K
+196.03%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Chairman of the Board
Independent Chairman of the Board
365.89K
+172.22%
Ms. Christine Dolan
Ms. Christine Dolan
Executive Vice President, General Manager - Cygnus Technologies
Executive Vice President, General Manager - Cygnus Technologies
335.06K
+0.72%
Ms. Rebecca Buzzeo
Ms. Rebecca Buzzeo
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
224.73K
-28.71%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
North America
29.27M
62.47%
Asia Pacific
10.56M
22.53%
Europe, the Middle East and Africa
6.88M
14.68%
Latin and Central America
146.00K
0.31%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 14 de jun
Atualizado em: sáb, 14 de jun
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
GTCR Golder Rauner, LLC
14.00%
12 West Capital Management, L.P.
8.70%
The Vanguard Group, Inc.
6.52%
BlackRock Institutional Trust Company, N.A.
5.81%
Braidwell LP
5.80%
Other
59.18%
Investidores
Investidores
Proporção
GTCR Golder Rauner, LLC
14.00%
12 West Capital Management, L.P.
8.70%
The Vanguard Group, Inc.
6.52%
BlackRock Institutional Trust Company, N.A.
5.81%
Braidwell LP
5.80%
Other
59.18%
Tipos de investidores
Investidores
Proporção
Hedge Fund
29.22%
Investment Advisor
24.05%
Investment Advisor/Hedge Fund
16.48%
Private Equity
14.00%
Individual Investor
6.22%
Corporation
4.77%
Research Firm
4.09%
Pension Fund
0.34%
Bank and Trust
0.32%
Other
0.51%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
558
143.67M
99.79%
-29.37M
2025Q1
589
133.65M
92.84%
-44.45M
2024Q4
580
144.56M
101.93%
-33.57M
2024Q3
603
148.21M
104.79%
-33.05M
2024Q2
611
152.09M
114.44%
-19.50M
2024Q1
609
139.87M
105.40%
-26.88M
2023Q4
621
137.21M
103.78%
-26.31M
2023Q3
641
137.53M
104.23%
-17.92M
2023Q2
646
129.68M
98.32%
-22.48M
2023Q1
633
130.54M
99.07%
-18.12M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
GTCR Golder Rauner, LLC
20.15M
14%
--
--
Mar 31, 2025
12 West Capital Management, L.P.
12.52M
8.7%
+930.00K
+8.02%
Mar 31, 2025
The Vanguard Group, Inc.
11.64M
8.08%
-162.48K
-1.38%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.36M
5.81%
-121.20K
-1.43%
Mar 31, 2025
Braidwell LP
8.35M
5.8%
--
--
Mar 31, 2025
Hudson View Capital LLC
6.87M
4.77%
+6.87M
--
May 21, 2025
Mackenzie Investments
6.11M
4.25%
-69.09K
-1.12%
Mar 31, 2025
Renaissance Technologies LLC
4.11M
2.86%
+138.50K
+3.49%
Mar 31, 2025
Mirabella Financial Services LLP
3.74M
2.6%
+3.74M
--
Mar 31, 2025
Two Sigma Investments, LP
3.67M
2.55%
+3.35M
+1026.80%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Royce Quant Small-Cap Quality Value ETF
0.38%
Global X Genomics & Biotechnology ETF
0.36%
JPMorgan Fundamental Data Science Small Core ETF
0.12%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Proshares Ultra Russell 2000
0.01%
Schwab U.S. Small-Cap ETF
0.01%
Ver Mais
Royce Quant Small-Cap Quality Value ETF
Proporção0.38%
Global X Genomics & Biotechnology ETF
Proporção0.36%
JPMorgan Fundamental Data Science Small Core ETF
Proporção0.12%
ProShares Ultra Nasdaq Biotechnology
Proporção0.04%
Invesco Nasdaq Biotechnology ETF
Proporção0.04%
iShares Biotechnology ETF
Proporção0.03%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.02%
iShares Russell 2000 Value ETF
Proporção0.02%
Proshares Ultra Russell 2000
Proporção0.01%
Schwab U.S. Small-Cap ETF
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
